Picture EBD Group BIO-Europe Spring 2021 Digital 650x80
Document › Details

Exact Therapeutics AS. (1/29/21). "Press Release: Exact Therapeutics Announces Change of CFO with Departure of Stig Jarle Pettersen at the End of His Contracted Period". Oslo & London.

Organisation Organisation Exact Therapeutics AS
Products Product Acoustic Cluster Therapy (ACT® sonoporation)
  Product 2 financial services
Persons Person Hayhurst, Richard (Hayhurst Media 200705)
  Person 2 Hasan, Rafiq (Exact Therapeutics 202006– CEO before Bayer + Novartis)

EXACT THERAPEUTICS AS (“EXACT-Tx” or the “Company”), a clinical stage precision medicine company today announced that the company’s CFO Stig Jarle Pettersen, engaged as a part time consultant via his company CFO For Hire AS, will leave the company on January 31st 2021 at the end of his contracted period. EXACT Tx thanks Stig for his valuable contribution since joining the company in January 2019 and in particular for his support during the successful financing and listing on the Merkur Market (Euronext growth) in July 2020.

The process of hiring a full time CFO is ongoing and Ole Fegth of Abaci AS will assume CFO responsibilities for the company until ad interim.

About ACT®

• ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent.

ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration.

• Initial focus of the company is oncology, however the ACT® platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes.


EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions.

For more information contact:

Dr Rafiq Hasan
CEO EXACT Therapeutics

Richard Hayhurst/Janet Joy
Tel +44 7711 821527

Record changed: 2021-02-06


Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for Exact Therapeutics AS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe Spring 2021 Digital 650x80

» top